ERIC SCHNAKENBERG: Open Payments
NPI 1831128206 · HALFMOON, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$55,797 in 194 payments from 24 companies in 2025. Trend: 2023 $51,577 · 2024 $32,328 · 2025 $55,797
Speaker / faculty: $46,750Travel & lodging: $4,766Food & beverage: $4,281
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 103 | $53,911 |
| ABBVIE INC. | 17 | $330 |
| AstraZeneca Pharmaceuticals LP | 9 | $328 |
| PFIZER INC. | 13 | $196 |
| Novo Nordisk Inc | 8 | $183 |
| Lilly USA, LLC | 8 | $135 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $101 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $86 |
| Abbott Laboratories | 3 | $66 |
| Amgen Inc. | 3 | $61 |
Products named: AREXVY, SHINGRIX, PENMENVY, FARXIGA, VRAYLAR, NURTEC ODT, QULIPTA, Wegovy.
Industry payments across NY — which companies pay providers there.
